Background: Histologic healing is emerging as a new therapeutic goal in both routine practice and clinical trials in ulcerative colitis (UC). However, it requires repeated endoscopies and biopsies. Faecal calprotectin is a non-invasive marker of mucosal healing (endoscopic and histologic healing).
measured in 6 of 12 studies (50%) with the same kit, while the remaining six studies adopted individually different kits. A clear correlation between faecal calprotectin levels and histology was showed in all included studies. Eleven different faecal calprotectin cut-off points were identified to distinguish histological remission from histological activity, ranging from 40.5 to 250 μg/g.
Conclusions:
Faecal calprotectin can be used to predict histologic remission in patients with UC, but the cut-off level varies across studies, according to the test used to measure this biomarker and according to the definition of histologic remission.
Larger prospective studies using validated histologic indexes are needed to identify a globally accepted faecal calprotectin cut-off level to discriminate between histologic remission and histologically active disease.
| INTRODUC TI ON
Ulcerative colitis (UC) is a chronic disease with a remitting and relapsing course. 1 In recent years, the therapeutic target of inflammatory bowel diseases (IBD) has considerably evolved, moving from simple control of symptoms to tight control of the inflammatory state. 2, 3 While treat to target recommendations did not consider histologic healing as a target but rather as a valid and useful way to assess inflammation, there is growing interest for histologic healing in UC. 3 Histologic healing is associated with better clinical outcomes including reduced risks of hospitalisation, colectomy and colorectal cancer. 4, 5 Colonoscopy currently represents the gold standard for disease monitoring, as it allows to evaluate endoscopic healing and to perform biopsies for histologic analysis. 6 However, colonoscopy is a relatively invasive procedure, and it is poorly tolerated by patients. 7 For this reason, non-invasive tests such as faecal calprotectin (FC) have been proposed to monitor these patients in order to reduce the number of endoscopic procedures. FC is a non-invasive marker of disease activity. It can easily be measured in stool samples and has a good correlation with endoscopic scores in both Crohn's disease (CD) and UC. 8, 9 Three randomised clinical trials showed that biochemical monitoring of disease activity through FC levels predicted disease outcomes and the onset of relapses, allowing to guide therapeutic decisions and promptly modify patient therapy. [10] [11] [12] Several studies looked at the association between faecal calprotectin and histologic healing in UC and identified different FC cut-off thresholds. [13] [14] [15] However, these studies were very heterogeneous as they differed for outcomes measures, study population, histologic scores, definition of histologic remission, kits and normal cut-off points of faecal calprotectin. [13] [14] [15] The purpose of our systematic review is to provide an overview of available studies in order to better understand the correlation between faecal calprotectin levels and histologic activity in patients with UC.
| ME THODS

| Search strategy and study selection
This work was performed in accordance with the guidance specified in the Cochrane Handbook and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for reporting of systematic reviews. 16, 17 The study protocol was submitted on the PROSPERO international prospective register of systematic reviews. We searched PubMed/MEDLINE, EMBASE and Web of Science through September 2019 to identify all studies meeting the following inclusion criteria: (a) including adult and paediatric patients with confirmed diagnosis of UC; (b) reporting the definition of histologic remission and (c) assessing the correlation between FC values and histologic analysis, determining a FC cut-off level to predict histologic activity of disease. Studies were identified matching 'IBD', 'inflammatory bowel disease', 'UC' or 'ulcerative colitis' with the following search terms: 'faecal calprotectin', 'calpro', 'histology', 'histo', 'histologic activity', 'histologic remission' 'histologic healing', 'cut-off', 'Geboes score', 'Nancy index' or 'Robarts histopathologic score'. The search focused on full-text papers. Abstracts were selected when relevant.
Additional publications were identified through careful examination of reference lists. No language and publication date restrictions were imposed. After removing duplicates from our search, two authors (FD and SB) independently screened each potential title, abstract and/or full manuscript to determine whether they were eligible for inclusion. In case of disagreement, eligibility was determined by a third author (LPB or SD). 
| Data extraction
| RE SULTS
| Search results and study population
The flow chart of the search and selection process is shown in Table 1 . Two thousand and ninetyfour records were obtained (PubMed/MEDLINE: 596; Embase: 851; Web of Science: 647). After removal of duplicates, nonrelevant studies and studies that did not report original data (eg review articles), 19 publications were scrutinised. Seven studies were excluded [18] [19] [20] [21] [22] [23] [24] : two studies did not separate patients with UC from those with CD; two studies did not define a FC cut-off point; while three studies did not report appropriate outcomes.
Finally, 12 studies met the inclusion criteria and were included in the review. [13] [14] [15] [25] [26] [27] [28] [29] [30] [31] [32] [33] The reviewers fully agreed on the selection of eligible articles. Three retrospective cohort studies [29] [30] [31] and nine prospective cohort studies [13] [14] [15] [25] [26] [27] [28] 32, 33 were investigated.
All studies were published in full-text format, except for a study that was published solely as an abstract. 27 One study 30 included paediatric patients, but data were not differentiated from those of adults. One study 14 analysed patients with CD and UC simultaneously, distinguishing data concerning the study population. One thousand one hundred sixty-eight patients were enrolled in the included studies.
| Quality of studies
Quality of the studies included in the systematic review according to the Newcastle-Ottawa Scale is summarised in Table 2 . The assessment of the quality of the studies was performed using the Newcastle-Ottawa Scale (NOS). 34 NOS is a tool that evaluates eight items:
'representativeness of the exposed cohorts', 'selection of the nonexposed cohort', 'ascertainment of exposure', 'demonstration that the outcome of interest was not present at start of study', 'comparability of cohorts on the basis of the design or analysis', 'assessment of the outcome', 'follow-up is long enough for outcomes to occur' and 'adequacy of the follow-up'. A star can be assigned to each item, with the exception of comparability that allows the assignment of two stars, obtaining a maximum score of nine stars. A high score indicates a greater quality of the study. Two NOS criteria, 'selection of the non-exposed cohort'
and 'comparability of cohorts on the basis of the design or analysis'
were not used as they were not applicable to the studies included in the review. Studies were defined as 'high quality studies' if they had an NOS score ≥6. Two authors (FD and SB) graded independently the studies and disagreements were discussed with a third party (LPB or SD) until their resolution. Only two studies 25, 33 were classified as high quality studies, while the others were not.
| Histologic scores and definition of histologic remission
Histologic remission was defined according to different scores:
Geboes score 35 (four studies 14, 25, 27 ), Nancy index 36 (two studies 28, 30 ) or nonvalidated scores (five studies 13, 15, 29, 32, 33 ). One study 31 had four definitions based on three scores (Geboes score, Nancy index and Robarts histopathologic index 37 ). The Geboes score cut-off value to define histologic remission was 3.1 (except for a study 27 that had two as threshold), while for the Nancy index the threshold value was ≤1 (Table 3 ). In the studies of Theede -The reported outcomes were not appropriate: 3 -A cut-off value for fecal calprotectin was not reported: 2 -The study population was not appropriate: 2 
| Correlation between faecal calprotectin levels and histology
Correlation between histology and faecal calprotectin is reported in Table 3 . FC was analysed through different methods. Eight studies used the enzyme-linked immunosorbent assay (ELISA) test 13, 15, [25] [26] [27] 29, 30, 32 :
the Bühlmann kit (Switzerland) was adopted in six trials, 13, 15, 25, 26, 30, 32 the Genova diagnostics kit (Asheville, NC) 29 in one trial and an unspecified kit in another one. 27 One study 31 Note: Items: 1, representativeness of the exposed cohort; 2, ascertainment of exposure; 3, demonstration that outcome of interest was not present at start of study; 4, assessment of outcome; 5, follow-up was long enough for outcomes to occur; 6, adequacy of follow-up (>75% follow-up, or description for those lost) TA B L E 2 Quality of the studies included in the systematic review according to the Newcastle-Ottawa scale Sweden), while the other studies dosed FC levels through quantum blue kit (Bühlmann), 14 fluorescence enzyme immunoassay test (Phadia EliA, Sweden) 33 or IBDoc® FCal (Bühlmann) 28 (Table 3 ). In all 12 studies 13 analysis. [13] [14] [15] [25] [26] [27] [28] [29] [30] [31] [32] [33] Seven studies 13, 14, 27, 29, 30, 32, 33 31 In the individual studies microscopic inflammation was found in a percentage of patients ranging from 11.6% to 57.1%, although they were considered in disease remission. Several FC cut-off points were found to predict the presence or absence of histologic activity with a high degree of accuracy. The lowest and the highest cut-off thresholds for predicting histologic remission were 40.5 and 250 μg/g respectively. 31 ,32
| D ISCUSS I ON
Twelve studies (1168 patients) were included in our review. Data confirm a clear correlation between FC levels and histologic activity of disease in adult patients with UC. As expected, FC was reduced in case of histologic remission and was significantly increased when microscopic inflammation was found, regardless of histologic score, FC cut-off levels, and FC kit used. Seven studies 14, [25] [26] [27] [28] 30, 31 used partially validated scores (Geboes score, Nancy index and Robarts histopathologic score) for histologic remission definition, while in six studies 13, 15, 29, 32, 33 histologic healing was based on nonvalidated scores. Comparative trials 31, 40, 41 revealed a strong correlation between Geboes score, Nancy index and Robarts score suggesting that the available validated scores may provide overlapping data. Instead, a study by Römkens et al 42 showed that the correlation between the nonvalidated scores and between the nonvalidated and validated scores was moderate, highlighting how the histologic score can influence patient management and therapeutic decisions. Dosage of FC levels was performed through different methods and the most commonly adopted test was ELISA.
Interestingly, semi-quantitative tests such as quantum blue and the new tool for home FC measurement (IBDoc) were also used. All these instruments have acceptable diagnostic accuracy 43, 44 despite significant variability between these techniques has been detected in several studies. 45, 46 For this reason, these instruments are not interchangeable, the use of different FC tests for patients' follow-up could result in measurement bias, and FC monitoring should always be performed with the same method. However, to date there are no data to demonstrate the superiority of one specific kit for FC dosage over another. In all included studies FC cut-off levels were detected in order to predict histologic activity/remission, but there was no agreement between the FC thresholds found. This was probably due to the small sample size of the studies and lack of standardisation. In fact, the included trials used different histologic scores, FC kits, collection times and storage methods. FC cut-off points predicting histologic remission ranged from 40.5 to 200 μg/g, while FC cut-off levels indicating histologic activity of disease varied from 72 to 250 μg/g. However, as shown in Table 3 The homogenisation of patient management with a standard of care is therefore increasingly necessary to guarantee the best results for patients. 47 Recently it has been proposed to dose intramucosal FC (iMC) levels in order to overcome the variability related to FC measurement.
A retrospective study by Guirguis et al 23 
| CON CLUS IONS
Several studies showed a clear correlation between histology and faecal calprotectin levels in adult patients with ulcerative colitis.
Faecal calprotectin represents a useful and non-invasive marker to predict histologic activity of disease in these patients, although a validated cut-off level to distinguish histologic remission from histologic activity has not yet been established. Large prospective studies using validated histologic scores and standardised methods of FC measurement are needed to confirm these data, to overcome the marked heterogeneity of current literature, and to define a globally accepted faecal calprotectin cut-off value. • Faecal calprotectin is positively related to the state of histologic disease activity in UC patients in all included studies. • There is a high heterogeneity between the studies regarding definitions of histologic healing and variability in the kits used for FC dosage. • A FC cut-off value ranging from 40.5 to 200 μg/g is able to accurately predict histologic remission of disease. • A FC cut-off level varying from 72 to 250 μg/g predicts histologic activity of disease. • FC is a promising surrogate marker to predict histologic activity of disease, although current literature has not yet identified an optimal FC cut-off. • FC dosage cannot completely replace endoscopy with biopsies in the monitoring of disease activity but can allow reduction in the number of performed colonoscopies.
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